COMMUNIQUÉS West-GlobeNewswire

GenMark Diagnostics Schedules Fourth Quarter and Full Year 2018 Financial Results Conference Call for February 21, 2019
07/02/2019
CARLSBAD, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Thursday, February 21, 2019 [...]
Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium
07/02/2019
Company to Highlight ARV-110 PROTAC™ Protein Degrader for the Treatment of Prostate Cancer NEW HAVEN, Conn., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of [...]
Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates
07/02/2019
Expanded pipeline with two investigational gene therapy programs licensed from the University of Massachusetts Medical School for the treatment of GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases First two patients [...]
Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results
07/02/2019
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to $113.0 million Including equity offering, ending [...]
Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Third-Quarter 2019 Results
07/02/2019
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019 Submit first IND in calendar 2020 SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“ [...]
Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding
07/02/2019
– Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients – –Thrombotic Event Rate of 9.7 Percent Across All Patients, No Thrombotic Events Observed Among Patients Who Re-started Oral Anticoagulation [...]
IntelGenx Strengthens Senior Management Team
07/02/2019
SAINT-LAURENT, Québec, Feb. 07, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT), today announced that it has strengthened its management team with the appointment of Dr. Rodolphe Obeid to [...]
Cytokinetics to Announce Fourth Quarter Results on February 21, 2019
07/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report fourth quarter results on February 21, 2019 at 4:00 PM Eastern Time [...]
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host Conference Call on 26 February 2019
07/02/2019
LONDON, Feb. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]
Participation de Merus au forum d’échange sur les soins de santé de Guggenheim
07/02/2019
UTRECHT, Pays-Bas, 07 févr. 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants complets à base d'anticorps bispécifiques ( [...]
Tetra Bio-Pharma Pursues Its Research Priorities Accelerating Other Drug Development Plans
07/02/2019
Last Week’s Agreement to Acquire PANAG Establishes Exhaustive Dermatology and Ophthalmic Product Portfolios ORLEANS, Ontario, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") ( [...]
Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring
07/02/2019
DUBLIN, Ireland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) provided clarification regarding the restructuring actions announced earlier today. As part of the restructuring plan, Avadel [...]
The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Seventh Annual Cell & Gene Therapy Investor Day
07/02/2019
WASHINGTON, D.C., Feb. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM) today announced the initial slate of presenting companies at its annual Cell & Gene Therapy [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
07/02/2019
Communiqué de Presse Information relative au nombre total de droits de vote et d'actions composant le capital social Dijon, le 7 février 2019 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases
07/02/2019
Servier exercised first of two steps under OSE-127 global licensing option agreement OSE-127, an IL-7R antagonist, is currently in Phase 1 clinical testing NANTES, France and PARIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- OSE [...]
Vital® Spotlights True Interoperability at HIMSS 2019 and Celebrates a KLAS No. 1 Ranking for Advanced Visualization
07/02/2019
MINNETONKA, Minn., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Vital, a Canon Group company, will demonstrate its powerful Vitrea ® Enterprise Imaging solution at this year's Healthcare Information and Management Systems Society [...]
Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
07/02/2019
GAITHERSBURG, Md., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the [...]
Coherus BioSciences Announces New Employment Inducement Grants
07/02/2019
REDWOOD CITY, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 6, 2019, the compensation committee of the company’s board of directors granted [...]
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
07/02/2019
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria. Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other antibiotic-resistant and [...]

Pages